{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:16:32Z","timestamp":1790770592517,"version":"4.1.0"},"reference-count":121,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thyroid eye disease (TED) is the most common extra thyroidal manifestation of Graves\u2019 disease (GD). It may also present in those who are hypothyroid or euthyroid. The characteristic clinical manifestations of TED, chemosis, lid swelling, proptosis, and diplopia, are driven by a combination of inflammation and extracellular matrix modification. It has recently emerged that 1 of the major drivers of this molecular signature is the overexpression of the IGF-1 receptor [IGF-1R]) on key effector cells in TED pathogenesis. The overexpression of the IGF-1R is coupled with a dysregulation of the IGF-1R axis, which links other pathways that modulate inflammation, such as fibrosis and extracellular matrix organization, in patients with TED. This overexpression is also found to persist from the acute stage into the chronic phase. Teprotumumab, a fully human IgG1 monoclonal antibody that inhibits the IGF-1R, recently gained approval in the United States for the treatment of TED. In phase 2 and phase 3 clinical studies, teprotumumab showed efficacy in reducing inflammation, proptosis, diplopia, and burden on quality of life in patients who were treated. Postintroduction studies have confirmed the results of the phase 2 and phase 3 studies. Since 2020, more than 5800 patients have been treated with teprotumumab, and it appears to be well tolerated. The American Thyroid Association and the European Thyroid Association have recommended it as first-line therapy for patients with moderate to severe TED who display features of proptosis and diplopia.<\/jats:p>","DOI":"10.1210\/endrev\/bnae018","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T19:38:20Z","timestamp":1717616300000},"page":"843-857","source":"Crossref","is-referenced-by-count":27,"title":["Teprotumumab for the Treatment of Thyroid Eye Disease"],"prefix":"10.1210","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4479-3033","authenticated-orcid":false,"given":"Shoaib","family":"Ugradar","sequence":"first","affiliation":[{"name":"Department of Orbit and Thyroid Eye Disease Thrive Health , Beverly Hills, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Malkhasyan","sequence":"additional","affiliation":[{"name":"Department of Orbit and Thyroid Eye Disease Thrive Health , Beverly Hills, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3435-8161","authenticated-orcid":false,"given":"Raymond S","family":"Douglas","sequence":"additional","affiliation":[{"name":"Department of Orbit and Thyroid Eye Disease Thrive Health , Beverly Hills, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"2024112123521410900_bnae018-B1","first-page":"43","article-title":"Clinical endocrinology in the islamic civilization in Iran","volume":"1","author":"Nabipour","year":"2003","journal-title":"Int J Endocrlnol Metab"},{"issue":"4","key":"2024112123521410900_bnae018-B2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol. Metab"},{"issue":"8","key":"2024112123521410900_bnae018-B3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"2024112123521410900_bnae018-B4","first-page":"283","article-title":"Quality of life and occupational disability in endocrine orbitopathy","volume":"106","author":"Ponto","year":"2009","journal-title":"Dtsch Arztebl Int"},{"issue":"5","key":"2024112123521410900_bnae018-B5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/cen.12060","article-title":"Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005","volume":"78","author":"Nystr\u00f6m","year":"2013","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"12","key":"2024112123521410900_bnae018-B6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrendo.2013.193","article-title":"Diagnosis and management of Graves disease: a global overview","volume":"9","author":"Bartalena","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2024112123521410900_bnae018-B7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2024112123521410900_bnae018-B8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"4","key":"2024112123521410900_bnae018-B9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves\u2019 disease: a meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"3","key":"2024112123521410900_bnae018-B10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/thy.2014.0475","article-title":"Role of the underlying thyroid disease on the phenotype of Graves\u2019 orbitopathy in a tertiary referral center","volume":"25","author":"Leo","year":"2015","journal-title":"Thyroid"},{"issue":"1","key":"2024112123521410900_bnae018-B11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13643-020-01459-7","article-title":"Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature","volume":"9","author":"Mu\u00f1oz-Ortiz","year":"2020","journal-title":"Syst Rev"},{"issue":"11","key":"2024112123521410900_bnae018-B12","first-page":"1442","article-title":"Hyperthyroid vs hypothyroid eye disease: the same severity and activity","volume":"25","author":"Kashkouli","year":"2011","journal-title":"Eye(Lond)"},{"issue":"8","key":"2024112123521410900_bnae018-B13","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2007.137265","article-title":"Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy","volume":"93","author":"Eckstein","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2024112123521410900_bnae018-B14","first-page":"36","article-title":"Management of exophthalmos and related ocular changes in Graves\u2019 disease","volume":"6","author":"RUNDLE","year":"1957","journal-title":"Metabolism"},{"issue":"5","key":"2024112123521410900_bnae018-B15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/IOP.0000000000001087","article-title":"Noninflammatory thyroid eye disease","volume":"35","author":"Ugradar","year":"2019","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"4S Suppl 1","key":"2024112123521410900_bnae018-B16","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/IOP.0000000000001147","article-title":"Phenotypes of thyroid eye disease","volume":"34","author":"Uddin","year":"2018","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"9","key":"2024112123521410900_bnae018-B17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.eprac.2022.06.003","article-title":"Inflammatory and noninflammatory thyroid eye disease: comparison of disease signs, symptoms, and quality of life in patients in the United States","volume":"28","author":"Wang","year":"2022","journal-title":"Endocr Pract"},{"issue":"9","key":"2024112123521410900_bnae018-B18","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","article-title":"Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression","volume":"35","author":"Ugradar","year":"2020","journal-title":"Eye"},{"key":"2024112123521410900_bnae018-B19","volume-title":"American Acdemy of Ophthalmology","author":"Ugradar","year":"2022"},{"issue":"1","key":"2024112123521410900_bnae018-B20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40123-019-00226-9","article-title":"Current understanding of the progression and management of thyroid associated orbitopathy: a systematic review","volume":"9","author":"Hodgson","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"2024112123521410900_bnae018-B21","doi-asserted-by":"crossref","DOI":"10.1097\/IOP.0000000000001087","article-title":"Noninflammatory thyroid eye disease","volume":"35","author":"Ugradar","year":"2019","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"6","key":"2024112123521410900_bnae018-B22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/IOP.0000000000001098","article-title":"Measurement of medial wall bowing and clinical associations in thyroid eye disease","volume":"34","author":"Bokman","year":"2018","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"5","key":"2024112123521410900_bnae018-B23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/IOP.0000000000001292","article-title":"Bony orbital volume expansion in thyroid eye disease","volume":"35","author":"Ugradar","year":"2019","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"5","key":"2024112123521410900_bnae018-B24","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1177\/1120672119852322","article-title":"Orbital fat expansion in thyroid eye disease is related to age","volume":"30","author":"Ugradar","year":"2019","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"2024112123521410900_bnae018-B25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.survophthal.2009.06.009","article-title":"Immunopathogenesis of thyroid eye disease: emerging paradigms","volume":"55","author":"Naik","year":"2010","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"2024112123521410900_bnae018-B26","first-page":"317","article-title":"Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation","volume":"151","author":"Smith","year":"1997","journal-title":"Am J Pathol"},{"issue":"3","key":"2024112123521410900_bnae018-B27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archopthalmol.2011.1271","article-title":"Thyroid-associated periorbitopathy: eyebrow fat and soft tissue expansion in patients with thyroid-associated orbitopathy","volume":"130","author":"Papageorgiou","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"2024112123521410900_bnae018-B28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/IOP.0000000000001511","article-title":"Temporal fat pad volume in patients with thyroid eye disease","volume":"36","author":"Choudhary","year":"2020","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"9","key":"2024112123521410900_bnae018-B29","doi-asserted-by":"crossref","first-page":"e3809","DOI":"10.1097\/GOX.0000000000003809","article-title":"Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab","volume":"9","author":"Ugradar","year":"2021","journal-title":"Plast Reconstr surgery Glob Open"},{"issue":"2","key":"2024112123521410900_bnae018-B30","first-page":"222","article-title":"Immunohistochemical analysis of the retrobulbar tissues in Graves\u2019 ophthalmopathy","volume":"75","author":"Weetman","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"2024112123521410900_bnae018-B31","doi-asserted-by":"crossref","first-page":"E400","DOI":"10.1210\/jc.2011-2697","article-title":"Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in graves\u2019 ophthalmopathy","volume":"97","author":"Van Steensel","year":"2012","journal-title":"J. Clin. Endocrinol Metab"},{"issue":"1","key":"2024112123521410900_bnae018-B32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2009-1614","article-title":"Increased generation of fibrocytes in thyroid-associated ophthalmopathy","volume":"95","author":"Douglas","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024112123521410900_bnae018-B33","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J Immunol"},{"issue":"8","key":"2024112123521410900_bnae018-B34","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"2024112123521410900_bnae018-B35","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1210\/jc.2013-3977","article-title":"Regulation of IL-1 receptor antagonist by TSH in fibrocytes and orbital fibroblasts","volume":"99","author":"Li","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024112123521410900_bnae018-B36","doi-asserted-by":"crossref","first-page":"e75100","DOI":"10.1371\/journal.pone.0075100","article-title":"Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions","volume":"8","author":"Raychaudhuri","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"2024112123521410900_bnae018-B37","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1167\/iovs.18-23951","article-title":"CD34\u2014orbital fibroblasts from patients with thyroid-associated ophthalmopathy modulate TNF-\u03b1 expression in CD34 + fibroblasts and fibrocytes","volume":"59","author":"Lu","year":"2018","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"31","key":"2024112123521410900_bnae018-B38","doi-asserted-by":"crossref","first-page":"22910","DOI":"10.1074\/jbc.M703597200","article-title":"Differentiation of human circulating fibrocytes as mediated by transforming growth factor-\u03b2 and peroxisome proliferator-activated receptor","volume":"282","author":"Hong","year":"2007","journal-title":"J Biol Chem"},{"issue":"1","key":"2024112123521410900_bnae018-B39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13317-011-0025-9","article-title":"In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70)","volume":"3","author":"Furmaniak","year":"2012","journal-title":"Auto Immun Highlights"},{"issue":"1","key":"2024112123521410900_bnae018-B40","first-page":"543","article-title":"Update on thyroid eye disease and management","volume":"3","author":"Bothun","year":"2009","journal-title":"Clin Ophthalmol"},{"issue":"18","key":"2024112123521410900_bnae018-B41","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"39","key":"2024112123521410900_bnae018-B42","doi-asserted-by":"crossref","first-page":"26447","DOI":"10.1074\/jbc.M109.003616","article-title":"Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: CONTRIBUTORY ROLE IN HYALURONAN ACCUMULATION IN THYROID DYSFUNCTION","volume":"284","author":"Zhang","year":"2009","journal-title":"J Biol Chem"},{"issue":"3","key":"2024112123521410900_bnae018-B43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40618-020-01353-y","article-title":"Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves\u2019 orbitopathy","volume":"44","author":"Nicol\u00ec","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2024112123521410900_bnae018-B44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/a-1525-2070","article-title":"Predicting the course of graves\u2019 orbitopathy using serially measured TSH-receptor autoantibodies by automated binding immunoassays and the functional bioassay","volume":"53","author":"St\u00f6hr","year":"2021","journal-title":"Horm Metab Res"},{"issue":"2","key":"2024112123521410900_bnae018-B45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/thy.2010.0123","article-title":"Thyrotropin receptor-stimulating Graves\u2019 disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves\u2019 ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways","volume":"21","author":"Van Zeijl","year":"2011","journal-title":"Thyroid"},{"key":"2024112123521410900_bnae018-B46","first-page":"160008","article-title":"Thyroid antibody-negative euthyroid Graves\u2019 ophthalmopathy","volume":"2016","author":"Tabasum","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"4","key":"2024112123521410900_bnae018-B47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","article-title":"Autoantibodies to igf-1 binding sites in thyroid associated ophthalmopathy","volume":"16","author":"Weightman","year":"1993","journal-title":"Autoimmunity"},{"issue":"2","key":"2024112123521410900_bnae018-B48","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1210\/endo-119-2-940","article-title":"Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves\u2019-IgG","volume":"119","author":"Tramontano","year":"1986","journal-title":"Endocrinology"},{"key":"2024112123521410900_bnae018-B49","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol"},{"issue":"2","key":"2024112123521410900_bnae018-B50","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1210\/jc.2012-1771","article-title":"Autoantibodies to the IGF1 receptor in Graves\u2019 orbitopathy","volume":"98","author":"Minich","year":"2013","journal-title":"J. Clin Endocrinol Metab"},{"issue":"5","key":"2024112123521410900_bnae018-B51","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/thy.2018.0089","article-title":"Evidence that Graves\u2019 ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors","volume":"28","author":"Marcus-Samuels","year":"2018","journal-title":"Thyroid"},{"issue":"10","key":"2024112123521410900_bnae018-B52","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/jc.2004-0716","article-title":"Immunoglobulins from patients with graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024112123521410900_bnae018-B53","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"issue":"3","key":"2024112123521410900_bnae018-B54","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1172\/JCI113672","article-title":"Thyroid-stimulating hormone and insulin-like growth factor-1 synergize to elevate 1,2-diacylglycerol in rat thyroid cells. Stimulation of DNA synthesis via interaction between lipid and adenylyl cyclase signal transduction systems","volume":"82","author":"Brenner-Gati","year":"1988","journal-title":"J Clin Invest"},{"issue":"5","key":"2024112123521410900_bnae018-B55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1089\/thy.2009.0447","article-title":"Effects of thyrotropin and thyrotropin-receptor-stimulating Graves\u2019 disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves\u2019 ophthalmopathy patients","volume":"20","author":"Van Zeijl","year":"2010","journal-title":"Thyroid"},{"issue":"5","key":"2024112123521410900_bnae018-B56","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1210\/jc.2011-2890","article-title":"A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves\u2019 orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody","volume":"97","author":"Kumar","year":"2012","journal-title":"J. Clin Endocrinol Metab"},{"key":"2024112123521410900_bnae018-B57","first-page":"657","article-title":"Prednisone therapy in ophthalmic Graves\u2019 disease","volume":"81","author":"EVANS","year":"1961","journal-title":"Trans Ophthalmol Soc U K (1962)"},{"issue":"2","key":"2024112123521410900_bnae018-B58","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024112123521410900_bnae018-B59","first-page":"168","article-title":"Management of Graves\u2019 ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"2024112123521410900_bnae018-B60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","article-title":"Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study","volume":"158","author":"van Geest","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2024112123521410900_bnae018-B61","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024112123521410900_bnae018-B62","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"2024112123521410900_bnae018-B63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/105072504774193276","article-title":"Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves\u2019 ophthalmopathy","volume":"14","author":"Marin\u00f3l","year":"2004","journal-title":"Thyroid"},{"issue":"6","key":"2024112123521410900_bnae018-B64","doi-asserted-by":"crossref","first-page":"e220189","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"2","key":"2024112123521410900_bnae018-B65","first-page":"258","article-title":"Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells1","volume":"52","author":"Nagai","year":"1992","journal-title":"Cancer Res"},{"issue":"4","key":"2024112123521410900_bnae018-B66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024112123521410900_bnae018-B67","first-page":"725","article-title":"Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients","volume":"14","author":"Li","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1 SUPPL","key":"2024112123521410900_bnae018-B68","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.asj.2005.09.012","article-title":"The anatomy of the aging face: volume loss and changes in 3-dimensional topography","volume":"26","author":"Coleman","year":"2006","journal-title":"Aesthetic Surg. J"},{"key":"2024112123521410900_bnae018-B69","first-page":"205","article-title":"Mycophenolate mofetil (CellCept\u00ae) in combination with low dose prednisolone in moderate to severe graves\u2019 orbitopathy","volume":"9","author":"Rajabi","year":"2022","journal-title":"Front. Med (Lausanne)"},{"issue":"6","key":"2024112123521410900_bnae018-B70","doi-asserted-by":"crossref","first-page":"L13","DOI":"10.1530\/EJE-21-0861","article-title":"Comment on the 2021 EUGOGO clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Smith","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2024112123521410900_bnae018-B71","doi-asserted-by":"crossref","first-page":"L15","DOI":"10.1530\/EJE-21-0967","article-title":"Response to comment by Smith on the 2021 EUGOGO guidelines","volume":"185","author":"Kahaly","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2024112123521410900_bnae018-B72","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024112123521410900_bnae018-B73","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024112123521410900_bnae018-B74","first-page":"CD012984","article-title":"Tocilizumab for thyroid eye disease","volume":"2018","author":"Hamed Azzam","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2024112123521410900_bnae018-B75","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1345\/aph.1L268","article-title":"Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis","volume":"42","author":"Plushner","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2024112123521410900_bnae018-B76","first-page":"4371","article-title":"Leukemia inhibitory factor and interleukin-6 trigger the same immediate early response, including tyrosine phosphorylation, upon induction of myeloid leukemia differentiation","volume":"11","author":"Lord","year":"1991","journal-title":"Mol Cell Biol"},{"issue":"Suppl","key":"2024112123521410900_bnae018-B77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0896-8411(89)90128-5","article-title":"Intrathyroidal cytokine production in thyroid disease","volume":"2","author":"Grubeck-Loebenstein","year":"1989","journal-title":"J Autoimmun"},{"issue":"3","key":"2024112123521410900_bnae018-B78","first-page":"1194","article-title":"Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy","volume":"85","author":"Hiromatsu","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024112123521410900_bnae018-B79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/08916939708996275","article-title":"High circulating IL-6 level in Graves\u2019 ophthalmopathy","volume":"25","author":"Moln\u00e1r","year":"2009","journal-title":"Autoimmunity"},{"issue":"2","key":"2024112123521410900_bnae018-B80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2024112123521410900_bnae018-B81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2024112123521410900_bnae018-B82","doi-asserted-by":"crossref","first-page":"101383","DOI":"10.1016\/j.beem.2020.101383","article-title":"Thyroid-associated ophthalmopathy: emergence of teprotumumab as a promising medical therapy","volume":"34","author":"Smith","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2024112123521410900_bnae018-B83","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41433-018-0321-y","article-title":"Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis","volume":"33","author":"Douglas","year":"2019","journal-title":"Eye"},{"issue":"8","key":"2024112123521410900_bnae018-B84","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40262-021-01003-3","article-title":"Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor-blocking antibody, in thyroid eye disease","volume":"60","author":"Xin","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2024112123521410900_bnae018-B85","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N. Engl J Med"},{"issue":"5","key":"2024112123521410900_bnae018-B86","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1167\/iovs.07-1030","article-title":"A new and validated CT-based method for the calculation of orbital soft tissue volumes","volume":"49","author":"Regensburg","year":"2008","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"2","key":"2024112123521410900_bnae018-B87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","article-title":"Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease","volume":"106","author":"Jain","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"2024112123521410900_bnae018-B88","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024112123521410900_bnae018-B89","author":"Subramanian"},{"issue":"8","key":"2024112123521410900_bnae018-B90","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease","volume":"36","author":"Ugradar","year":"2022","journal-title":"Eye (Lond)"},{"issue":"5","key":"2024112123521410900_bnae018-B91","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/01676830.2021.1933081","article-title":"Teprotumumab for chronic thyroid eye disease","volume":"41","author":"Ozzello","year":"2022","journal-title":"Orbit"},{"issue":"1","key":"2024112123521410900_bnae018-B92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024112123521410900_bnae018-B93","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/IOP.0000000000001942","article-title":"The \u201cQuiet TED\u201d-a special subgroup of thyroid eye disease","volume":"37","author":"I\u00f1iguez-Ariza","year":"2021","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2024112123521410900_bnae018-B94","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s40618-020-01258-w","article-title":"Asymmetry indicates more severe and active disease in Graves\u2019 orbitopathy: results from a prospective cross-sectional multicentre study","volume":"43","author":"Perros","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2024112123521410900_bnae018-B95","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/eye.2015.76","article-title":"Which factors are associated with quality of life in patients with Graves\u2019 orbitopathy presenting for orbital decompression surgery?","volume":"29","author":"Wickwar","year":"2015","journal-title":"Eye"},{"issue":"11","key":"2024112123521410900_bnae018-B96","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0161-6420(88)32978-7","article-title":"Dysthyroid optic neuropathy: the crowded orbital apex syndrome","volume":"95","author":"Neigel","year":"1988","journal-title":"Ophthalmology"},{"issue":"2","key":"2024112123521410900_bnae018-B97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3341\/kjo.2012.26.2.73","article-title":"Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy","volume":"26","author":"Jeon","year":"2012","journal-title":"Korean J Ophthalmol"},{"issue":"12","key":"2024112123521410900_bnae018-B98","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/bjo.80.12.1042","article-title":"Retrobulbar pressures measured during surgical decompression of the orbit","volume":"80","author":"Otto","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"2024112123521410900_bnae018-B99","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2024112123521410900_bnae018-B100","doi-asserted-by":"crossref","first-page":"101111","DOI":"10.1016\/j.ajoc.2021.101111","article-title":"Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study","volume":"23","author":"Sears","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2024112123521410900_bnae018-B101","doi-asserted-by":"crossref","first-page":"101075","DOI":"10.1016\/j.ajoc.2021.101075","article-title":"Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: a report of two cases","volume":"22","author":"Chiou","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"2024112123521410900_bnae018-B102","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1097\/WNO.0000000000001298","article-title":"Visual recovery of dysthyroid optic neuropathy with teprotumumab","volume":"42","author":"Lopez","year":"2022","journal-title":"J Neuroophthalmol"},{"issue":"Suppl 1","key":"2024112123521410900_bnae018-B103","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1210\/clinem\/dgac168","article-title":"Teprotumumab and the evolving therapeutic landscape in thyroid eye disease","volume":"107","author":"Kossler","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2024112123521410900_bnae018-B104","doi-asserted-by":"crossref","first-page":"100744","DOI":"10.1016\/j.ajoc.2020.100744","article-title":"Early experience with teprotumumab for chronic thyroid eye disease","volume":"19","author":"Ozzello","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"2024112123521410900_bnae018-B105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of Graves\u2019 orbitopathy (GO) and relationship with thyroid disease","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2024112123521410900_bnae018-B106","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00002341-199406000-00002","article-title":"Involvement of the eyebrow fat pad in Graves\u2019 orbitopathy","volume":"10","author":"Goldberger","year":"1994","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"2024112123521410900_bnae018-B107","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/IOP.0b013e31822e9560","article-title":"Histopathology of brow fat in thyroid-associated orbitopathy","volume":"28","author":"Hwang","year":"2012","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"Supplement_1","key":"2024112123521410900_bnae018-B108","doi-asserted-by":"crossref","first-page":"A861","DOI":"10.1210\/jendso\/bvac150.1781","article-title":"RF35 | PSAT268 reversal of Graves\u2019 disease associated facial volume expansion and eyelid changes following teprotumumab therapy","volume":"6","author":"Ugradar","year":"2022","journal-title":"J Endocr Soc"},{"issue":"4","key":"2024112123521410900_bnae018-B109","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/clinem\/dgac627","article-title":"Teprotumumab-related hyperglycemia","volume":"108","author":"Amarikwa","year":"2022","journal-title":"J. Clin Endocrinol Metab"},{"issue":"3","key":"2024112123521410900_bnae018-B110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/WNO.0000000000001560","article-title":"Expert consensus on the use of teprotumumab for the management of thyroid eye disease using a modified-Delphi approach","volume":"42","author":"Douglas","year":"2022","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"2024112123521410900_bnae018-B111","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/IOP.0000000000001995","article-title":"Teprotumumab and hearing loss: case series and proposal for audiologic monitoring","volume":"38","author":"Belinsky","year":"2022","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"2","key":"2024112123521410900_bnae018-B112","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/0973-1075.156479","article-title":"Audiometric patterns in ototoxicity after radiotherapy and chemotherapy in patients of head and neck cancers","volume":"21","author":"Malgonde","year":"2015","journal-title":"Indian J Palliat Care"},{"issue":"8","key":"2024112123521410900_bnae018-B113","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/bjc.1998.226","article-title":"Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer","volume":"77","author":"Bokemeyer","year":"1998","journal-title":"Br J Cancer"},{"issue":"10","key":"2024112123521410900_bnae018-B114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1288\/00005537-198010001-00001","article-title":"Aminoglycoside ototoxicity in the human","volume":"90","author":"Fee","year":"1980","journal-title":"Laryngoscope"},{"issue":"1","key":"2024112123521410900_bnae018-B115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/149.1.23","article-title":"Risk factors for the development of auditory toxicity in patients receiving aminoglycosides","volume":"149","author":"Moore","year":"1984","journal-title":"J Infect Dis"},{"key":"2024112123521410900_bnae018-B116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"2024112123521410900_bnae018-B117","first-page":"669","volume-title":"Registries for Evaluating Patient Outcomes: A User's Guide","author":"Gliklich","year":"2014"},{"key":"2024112123521410900_bnae018-B118","author":"Quick Statistics About Hearing | NIDCD"},{"issue":"1","key":"2024112123521410900_bnae018-B119","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/thy.2023.0466","article-title":"A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease","volume":"34","author":"Douglas","year":"2024","journal-title":"Thyroid"},{"issue":"4","key":"2024112123521410900_bnae018-B120","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2021","journal-title":"Ophthalmology"},{"key":"2024112123521410900_bnae018-B121","author":"Ugradar"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnae018\/58862696\/bnae018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnae018\/60764153\/bnae018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnae018\/60764153\/bnae018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T23:52:49Z","timestamp":1732233169000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/45\/6\/843\/7688408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":121,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,5]]},"published-print":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnae018","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,6,5]]}}}